Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.

Expert opinion on pharmacotherapy - 1 Jul 2010

Rosell Rafael, Moran Teresa, Viteri Santiago, Carcereny Enric, Gasco Amaya, Quiroga Vanessa, Wei Jia, Camps Carlos, Massuti Bartomeu

Abstract excerpt

IMPORTANCE OF THE FIELD: Non-small-cell lung cancer (NSCLC) is a disseminated disease in 50% of cases, with a gloomy prognosis and median survivals of < 1 year. AREAS COVERED IN THIS REVIEW: Based on substantial advances, cancer biology insights and novel biotechnology tools, customized treatment provides hints that cisplatin-based treatment can be optimized in favorable subgroups of patients according to gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Erlotinib Hydrochloride

Share to Histone Chaperones

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Quinazolines

Source

Identifiers

PMID: 20486827
DOI: 10.1517/14656566.2010.482101

Genes

EGFR
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.PMID 20486827Read ↗

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.Semantic proximity Read ↗

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Semantic proximity Read ↗

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Semantic proximity Read ↗

Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to realitySemantic proximity Read ↗

Biomarkers in lung oncology.Semantic proximity Read ↗

A Novel Radio-Genomics Biomarker for Precision Epidermal Growth Factor Receptor Mutation Targeting Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.Semantic proximity Read ↗

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.Semantic proximity Read ↗

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.Semantic proximity Read ↗

[Driver gene mutation and targeted therapy of lung cancer].Semantic proximity Read ↗

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.Semantic proximity Read ↗

The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.